New treatment options for fibromyalgia: critical appraisal of duloxetine
Nurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Mu...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7e37398cd56049c5808e4f497c3f4657 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7e37398cd56049c5808e4f497c3f4657 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7e37398cd56049c5808e4f497c3f46572021-12-02T05:09:43ZNew treatment options for fibromyalgia: critical appraisal of duloxetine1176-63281178-2021https://doaj.org/article/7e37398cd56049c5808e4f497c3f46572008-06-01T00:00:00Zhttp://www.dovepress.com/new-treatment-options-for-fibromyalgia-critical-appraisal-of-duloxetin-a1849https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Nurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Munich, Germany; 3Department of Anesthesiology, University of Cologne, Germany; 4Center of Pain Therapy, Klinikum Saarbrücken gGmbH, Winterberg 1, Saarbrücken, GermanyAbstract: Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain, tender points, fatigue, and sleep disturbance. FMS leads to high disability levels, poor quality of life, and extensive use of medical care. Effective pharmacological treatment options are rare, and treatment effects are often of limited duration. Duloxetine is a new selective serotonin and norepinephrine reuptake inhibitor that is licensed for the treatment of pain in diabetic neuropathy. So far two randomized, placebo-controlled trials have investigated the short-term safety and efficacy of duloxetine 60 mg/day and 120 mg/day in patients suffering from FMS over a period of 12 weeks. Both dosages were superior to placebo in pain relief, and improvement in quality of life and depressive symptoms. The analgesic effect was largely independent of the antidepressant action of duloxetine. The higher dose of 120 mg/day further reduced the tender point count and elevated the tender point pain thresholds. Only mild to moderate adverse effects were reported. Duloxetine 60 mg/day and 120 mg/day has proven to be beneficial in the treatment of FMS symptoms. As true for other antidepressants further studies are needed to assess the long-term efficacy and safety of duloxetine as an additional pharmacological treatment option in FMS.Keywords: fibromyalgia syndrome, duloxetine, antidepressant, review, SNRI Nurcan ÜçeylerMartin OffenbächerFrank PetzkeWinfried HäuserClaudia SommerDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 3, Pp 525-529 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer New treatment options for fibromyalgia: critical appraisal of duloxetine |
| description |
Nurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Munich, Germany; 3Department of Anesthesiology, University of Cologne, Germany; 4Center of Pain Therapy, Klinikum Saarbrücken gGmbH, Winterberg 1, Saarbrücken, GermanyAbstract: Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain, tender points, fatigue, and sleep disturbance. FMS leads to high disability levels, poor quality of life, and extensive use of medical care. Effective pharmacological treatment options are rare, and treatment effects are often of limited duration. Duloxetine is a new selective serotonin and norepinephrine reuptake inhibitor that is licensed for the treatment of pain in diabetic neuropathy. So far two randomized, placebo-controlled trials have investigated the short-term safety and efficacy of duloxetine 60 mg/day and 120 mg/day in patients suffering from FMS over a period of 12 weeks. Both dosages were superior to placebo in pain relief, and improvement in quality of life and depressive symptoms. The analgesic effect was largely independent of the antidepressant action of duloxetine. The higher dose of 120 mg/day further reduced the tender point count and elevated the tender point pain thresholds. Only mild to moderate adverse effects were reported. Duloxetine 60 mg/day and 120 mg/day has proven to be beneficial in the treatment of FMS symptoms. As true for other antidepressants further studies are needed to assess the long-term efficacy and safety of duloxetine as an additional pharmacological treatment option in FMS.Keywords: fibromyalgia syndrome, duloxetine, antidepressant, review, SNRI |
| format |
article |
| author |
Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer |
| author_facet |
Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer |
| author_sort |
Nurcan Üçeyler |
| title |
New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_short |
New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_full |
New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_fullStr |
New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_full_unstemmed |
New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_sort |
new treatment options for fibromyalgia: critical appraisal of duloxetine |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/7e37398cd56049c5808e4f497c3f4657 |
| work_keys_str_mv |
AT nurcanampuumlampccedileyler newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT martinoffenbampaumlcher newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT frankpetzke newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT winfriedhampaumluser newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT claudiasommer newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine |
| _version_ |
1718400538623606784 |